Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries ...

After some six years at the post, Amgen’s finance chief is telegraphing his exit from the California pharma by early next ...

After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once ...

May 19 (Reuters) - Amgen said on Tuesday its chief financial officer, Peter Griffith, would retire, with Thomas Dittrich ...

Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an ...

Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a Neutral rating. The revision follows the biotech’s Q1 2026 earnings release and ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new ...

View Amgen Inc. AMGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Amgen named Thomas Dittrich, a former finance executive at the company, as its next chief financial officer. The biotechnology company said Tuesday that Dittrich will succeed Peter Griffith, who is ...

The U.S. Food and Drug Administration's Center for Drug Evaluation and Research (CDER) has proposed withdrawing approval of Amgen's drug for rare autoimmune diseases, ​citing a lack of proven ...